A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Clinical trial NCT03217812 · COMPLETED
Trial details
- NCT number
- NCT03217812
- Sponsor
- Janssen Research & Development, LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-23
- Primary completion
- 2020-07-02
- Enrollment
- 220
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.